Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC).
In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.
They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available...
This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant...
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use...